MedPath

GILEAD SCIENCES SL

🇺🇸United States
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy

Phase 3
Recruiting
Conditions
Endometrial Cancer
Interventions
First Posted Date
2024-07-03
Last Posted Date
2025-06-25
Lead Sponsor
Gilead Sciences
Target Recruit Count
520
Registration Number
NCT06486441
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

UC San Diego Medical Center, La Jolla, California, United States

and more 168 locations

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Phase 4
Recruiting
Conditions
HIV-1-infection
Interventions
Drug: F/TAF (High Dose Tablet)
Drug: B/F/TAF (Low Dose)
Drug: E/C/F/TAF (Low Dose)
Drug: F/TAF (Low Dose Tablet)
Drug: F/TAF (Lowest Dose Tablet)
Drug: F/TAF (High Dose TOS)
Drug: B/F/TAF (High Dose)
Drug: F/TAF (Low Dose TOS)
Drug: B/F/TAF (Lowest Dose TOS)
Drug: F/TAF (Lowest Dose TOS)
Drug: B/F/TAF (High Dose TOS)
Drug: 3rd ARV Agent
Drug: B/F/TAF (Low Dose TOS)
Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Drug: ATV
Drug: DRV
First Posted Date
2024-03-29
Last Posted Date
2025-05-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
350
Registration Number
NCT06337032
Locations
🇿🇼

University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe

🇦🇷

Helios Salud, Buenos Aires, Argentina

🇵🇦

Hospital del Niño, Panama City, Panama

and more 9 locations

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Phase 3
Active, not recruiting
Conditions
HIV-1-infection
Interventions
Drug: B/F/TAF
Drug: Placebo to match B/F/TAF
Drug: Placebo to match BIC/LEN
First Posted Date
2024-03-27
Last Posted Date
2024-12-27
Lead Sponsor
Gilead Sciences
Target Recruit Count
577
Registration Number
NCT06333808
Locations
🇺🇸

Pueblo Family Physicians, Phoenix, Arizona, United States

🇺🇸

Be Well Medical Center, Berkeley, California, United States

🇺🇸

Pacific Oaks Medical Group, Beverly Hills, California, United States

and more 99 locations

Study of GS-1427 in Participants With Moderately to Severely Active UC

Phase 2
Recruiting
Conditions
Ulcerative Colitis (UC)
First Posted Date
2024-07-22
Last Posted Date
2025-05-06
Lead Sponsor
Gilead Sciences Inc.
Target Recruit Count
84
Registration Number
2023-508304-38-00
Locations
🇩🇪

Universitaetsklinikum Ulm AöR, Ulm, Germany

🇩🇪

Studiengesellschaft BSF UG (haftungsbeschraenkt), Halle (Saale), Germany

🇩🇪

Universitaetsklinikum Schleswig-Holstein AöR, Kiel, Germany

and more 73 locations

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2023-12-12
Last Posted Date
2025-03-12
Lead Sponsor
Gilead Sciences
Target Recruit Count
254
Registration Number
NCT06167317
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

NEXT Austin, Austin, Texas, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 4 locations

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

Phase 4
Completed
Conditions
HIV-1-infection
Interventions
Drug: B/F/TAF
First Posted Date
2023-10-27
Last Posted Date
2025-05-07
Lead Sponsor
Gilead Sciences
Target Recruit Count
33
Registration Number
NCT06104306
Locations
🇺🇸

Franco Felizarta, MD, Bakersfield, California, United States

🇺🇸

BIOS Clinical Research, Palm Springs, California, United States

🇺🇸

UC San Diego AntiViral Research Center (AVRC), San Diego, California, United States

and more 15 locations

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Phase 2
Recruiting
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
First Posted Date
2023-10-26
Last Posted Date
2025-05-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
180
Registration Number
NCT06101342
Locations
🇺🇸

UCLA Vine Street Clinic, Los Angeles, California, United States

🇺🇸

UCSD AntiViral Research Center (AVRC), San Diego, California, United States

🇺🇸

University of Miami - Converge Miami Building, Miami, Florida, United States

and more 6 locations

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Phase 2
Recruiting
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
First Posted Date
2023-10-26
Last Posted Date
2025-04-03
Lead Sponsor
Gilead Sciences
Target Recruit Count
250
Registration Number
NCT06101329
Locations
🇺🇸

George Washington University Medical Faculty Associates, Washington, District of Columbia, United States

🇺🇸

UAB, 1917 Research Clinic, Birmingham, Alabama, United States

🇺🇸

UCSD Antiviral Research Center (AVRC), San Diego, California, United States

and more 8 locations

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumors
Interventions
First Posted Date
2023-10-13
Last Posted Date
2025-05-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
120
Registration Number
NCT06082960
Locations
🇺🇸

Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States

🇺🇸

SCRI Oncology Partners, Nashville, Tennessee, United States

🇺🇸

NEXT Oncology, San Antonio, Texas, United States

and more 3 locations

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Phase 3
Recruiting
Conditions
Primary Biliary Cholangitis
Interventions
Drug: Placebo
First Posted Date
2023-09-25
Last Posted Date
2025-05-23
Lead Sponsor
Gilead Sciences
Target Recruit Count
318
Registration Number
NCT06051617
Locations
🇺🇸

OM Research LLC, Lancaster, California, United States

🇺🇸

SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

🇺🇸

Cedar Sinai Medical Center, Los Angeles, California, United States

and more 55 locations
© Copyright 2025. All Rights Reserved by MedPath